Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Beam Therapeutics Inc. (BEAM : NSDQ)
 
 • Company Description   
Beam Therapeutics Inc. is a biotechnology company. It engages in developing precision genetic medicines through base editing. Beam Therapeutics Inc. is based in Cambridge, Massachusetts.

Number of Employees: 341

 
 • Price / Volume Information   
Yesterday's Closing Price: $35.19 Daily Weekly Monthly
20 Day Moving Average: 1,507,074 shares
Shares Outstanding: 70.27 (millions)
Market Capitalization: $2,472.70 (millions)
Beta: 1.59
52 Week High: $138.52
52 Week Low: $27.77
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -16.41% -5.87%
12 Week -49.99% -45.02%
Year To Date -55.84% -47.96%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
238 Main Street
-
CAMBRIDGE,MA 02142
USA
ph: 857-327-8775
fax: -
investors@beamtx.com http://www.beamtx.com
 
 • General Corporate Information   
Officers
John Evans - Chief Executive Officer and Director
Terry-Ann Burrell - Chief Financial Officer and Treasurer
Kristina Burow - Director
Graham Cooper - Director
Mark Fishman - Director

Peer Information
Beam Therapeutics Inc. (CORR.)
Beam Therapeutics Inc. (RSPI)
Beam Therapeutics Inc. (CGXP)
Beam Therapeutics Inc. (BGEN)
Beam Therapeutics Inc. (GTBP)
Beam Therapeutics Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 07373V105
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/09/22
Share - Related Items
Shares Outstanding: 70.27
Most Recent Split Date: (:1)
Beta: 1.59
Market Capitalization: $2,472.70 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.08 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-4.29 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 4.15% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/09/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.98
Price/Cash Flow: -
Price / Sales: 41.03
EPS Growth
vs. Year Ago Period: 69.85%
vs. Previous Quarter: -18.82%
Sales Growth
vs. Year Ago Period: 140,433.33%
vs. Previous Quarter: -83.49%
ROE
03/31/22 - -28.02
12/31/21 - -52.28
09/30/21 - -63.65
ROA
03/31/22 - -17.21
12/31/21 - -32.87
09/30/21 - -41.25
Current Ratio
03/31/22 - 5.66
12/31/21 - 5.96
09/30/21 - 9.29
Quick Ratio
03/31/22 - 5.66
12/31/21 - 5.96
09/30/21 - 9.29
Operating Margin
03/31/22 - -355.42
12/31/21 - -668.46
09/30/21 - -42,185.41
Net Margin
03/31/22 - -395.37
12/31/21 - -714.91
09/30/21 - -51,395.01
Pre-Tax Margin
03/31/22 - -395.37
12/31/21 - -714.91
09/30/21 - -51,395.01
Book Value
03/31/22 - 11.80
12/31/21 - 12.13
09/30/21 - 12.87
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©